200kms In 2days – All In The Name Of Cancer Research

200kms In 2days – All In The Name Of Cancer Research

At Schlam, our values run deep. It is ingrained into everything we do. One of our most poignant values at our organisation is “Walk in their shoes – to uncover the real problems, we listen, we empathise, and we learn.”

That’s why have pooled together six cycling enthusiasts from around the Schlam office who will take part in the 2022 MACA CANCER 200 RIDE FOR RESEARCH. We will be cycling in the shoes of Harry Perkins Institute of Medical Research in an effort to raise much-needed funds for vital medical cancer research.

The HARRY PERKINS INSTITUTE OF MEDICAL RESEARCH has made significant discoveries into the diseases that plague our families, in particular heart disease, diabetes and cancer. With over 200 researchers, scientists and doctors housed in two state-of-the-art research facilities, the Perkins creates a culture of innovation and collaboration. Teams dedicated to finding answers to defeat cancers are funded from the MACA Cancer 200 each year.

Our team, #TEAM SCHLAMMERTIME, which includes Director Ryan Schlam and CEO Matt Thomas, will take on the challenge of riding 200km in two days to fight cancer this October.

We know there is nothing as powerful as a group of people mobilised behind a deeply personal cause that drives them to achieve great things, but we cannot do it without support.

So far, we have enlisted the support of some of Schlam’s most passionate suppliers as event sponsors. IMS our Platinum sponsor.  Together with SSABMMA OFFSHOREMASKILLWMC ENGINEERINGMADDINGTON/CANNING VALE TOYOTA and BRAND IDEOLOGY

We will be very grateful if you would support #TEAM SCHLAMMERTIME and the Harry Perkins Institute by generously contributing to our teams fundraising efforts. After all, every single dollar can help researchers get one step closer to curing cancer.

Donations and information on #TEAM SCHLAMMERTIME  can be found via this link WWW.CANCER200.ORG.AU/SCHLAMMERTIME

Share the Post:

Latest News

Subscribe to News

"*" indicates required fields